According to reports, Novavax Pharmaceuticals said on Thursday that the company and its partner Serum Institute of India have applied to the World Health Organization to include its COVID-19 vaccine on the emergency use list.

Being included on the WHO emergency use list means that the vaccine is safe and effective, which is also a prerequisite for vaccine exports.

In the US stock market on Thursday, Novavax Pharmaceuticals opened higher. The increase has now expanded to 10%, with turnover exceeding 750 million US dollars.

Previously, Novavax Pharmaceuticals and the Serum Institute, the world's largest vaccine manufacturer, had promised to provide more than 1.1 billion doses of the vaccine to low- and middle-income countries.

Novavax Pharmaceuticals' COVID-19 vaccine showed an overall effectiveness of 90.4% in trials in the US and Mexico.